SAB BIOTHERAPEUTICS, INC. Fair Value Adjustment of Warrants
SAB BIOTHERAPEUTICS, INC. (SABS) reported Fair Value Adjustment of Warrants of $1.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $1.11M, a 77.19% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was $482.47K.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $3.25M, a 41.06% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$61.60M.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2025 was -$62.75M.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2024 was -$5.39M, a 211.65% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2023 was $4.82M.
- SAB BIOTHERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2022 was -$10.40M, a 350.52% decline from fiscal 2021.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.11M 10-Q · filed 2026-08-06 | $1.59M 10-Q · filed 2026-08-06 | $4.85M derived: sum of 3 quarters · filed 2026-08-06 | -$56.75M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $482.47K 10-Q · filed 2026-05-12 | $3.74M derived: sum of 2 quarters · filed 2026-05-12 | -$57.86M derived: sum of 3 quarters · filed 2026-05-12 | -$57.24M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$58.35M derived: sum of 2 quarters · filed 2026-03-09 | -$57.72M derived: sum of 3 quarters · filed 2026-08-06 | -$62.75M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | -$61.60M 10-Q · filed 2025-11-14 | -$60.97M derived: sum of 2 quarters · filed 2026-08-06 | -$66.01M 10-Q · filed 2025-11-14 | -$63.70M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $627.00K 10-Q · filed 2026-08-06 | $627.06K 10-Q · filed 2025-08-07 | -$4.41M 10-Q · filed 2026-08-06 | -$4.41M 10-Q · filed 2025-08-07 | -$2.10M derived: sum of 3 quarters · filed 2026-08-06 | -$2.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.04M 10-Q · filed 2026-05-12 | -$2.73M derived: sum of 2 quarters · filed 2026-05-12 | -$2.74M derived: sum of 3 quarters · filed 2026-05-12 | -$4.95M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.30M derived: sum of 2 quarters · filed 2026-03-09 | $83.21K derived: sum of 3 quarters · filed 2026-03-09 | -$5.39M 10-K · filed 2026-03-09 | ||
| 2024-09-30 | -$6.17K 10-Q · filed 2025-11-14 | -$2.22M derived: sum of 2 quarters · filed 2025-11-14 | -$7.69M 10-Q · filed 2025-11-14 | -$2.96M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$2.22M 10-Q · filed 2025-08-07 | -$7.69M 10-Q · filed 2025-08-07 | -$2.96M derived: sum of 3 quarters · filed 2025-08-07 | -$3.14M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$5.47M 10-Q · filed 2025-05-09 | -$741.15K derived: sum of 2 quarters · filed 2025-05-09 | -$919.91K derived: sum of 3 quarters · filed 2025-05-09 | -$562.40K derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.55M derived: sum of 2 quarters · filed 2025-03-31 | $4.91M derived: sum of 3 quarters · filed 2025-03-31 | $4.82M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$178.76K 10-Q · filed 2024-11-06 | $178.76K derived: sum of 2 quarters · filed 2024-11-06 | $96.17K 10-Q · filed 2024-11-06 | $59.59K derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $357.52K 10-Q · filed 2024-08-08 | $274.93K 10-Q · filed 2024-08-08 | $238.34K derived: sum of 3 quarters · filed 2024-08-08 | -$544.62K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$82.59K 10-Q · filed 2024-05-20 | -$119.17K derived: sum of 2 quarters · filed 2024-05-20 | -$902.13K derived: sum of 3 quarters · filed 2024-05-20 | -$2.63M derived: sum of 4 quarters · filed 2024-05-20 | ||
| 2022-12-31 | -$36.59K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$819.55K derived: sum of 2 quarters · filed 2024-03-29 | -$2.55M derived: sum of 3 quarters · filed 2024-03-29 | -$10.40M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | -$782.96K 10-Q · filed 2023-11-13 | -$2.51M derived: sum of 2 quarters · filed 2023-11-13 | -$10.36M 10-Q · filed 2023-11-13 | -$4.72M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$1.73M 10-Q · filed 2023-08-21 | -$9.58M 10-Q · filed 2023-08-21 | -$3.93M derived: sum of 3 quarters · filed 2023-08-21 | -$3.93M derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-03-31 | -$7.85M 10-Q · filed 2023-05-15 | -$2.20M derived: sum of 2 quarters · filed 2023-05-15 | -$2.20M derived: sum of 3 quarters · filed 2023-05-15 | -$256.22K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $5.65M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $5.65M derived: sum of 2 quarters · filed 2023-04-28 | $7.59M derived: sum of 3 quarters · filed 2023-04-28 | $4.15M 10-K/A · filed 2023-04-28 | ||
| 2021-09-30 | -$1.79K 10-Q · filed 2021-11-22 | $1.95M derived: sum of 2 quarters · filed 2021-11-22 | -$1.50M 10-Q · filed 2021-11-22 | |||
| 2021-06-30 | $1.95M 10-Q · filed 2021-08-09 | -$1.49M 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | -$3.44M 10-Q · filed 2021-05-21 | |||||
| 2020-12-31 | $0.00 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |